Posters feature innovative technologies that address limitations of gene therapy production
NewBiologix SA, a technology innovation company pioneering innovative solutions to enable efficient, cost-effective and large-scale production of viral vectors for gene therapy, today announced that two abstracts have been selected for presentation at the 31st Annual European Society for Gene & Cell Therapy Congress (ESGCT), taking place October 22-25, 2024, at La Nuvola in Rome, Italy.
Poster presentation details are as follows:
Generation and Characterization of a HEK293 Cell Line for rAAV production.
- Session Name: Poster Session I
- Session Date: Tuesday, October 22, 2024
- Presentation Time: 19:30 to 21:00 CEST
- Room: Concourse Level I & Mezzanine Concourse
- Poster ID: P0039
An Integrated Platform for the Analysis and Quality Control of rAAV Vectors Based on Long-Read Sequencing.
- Session Name: Poster Session II
- Session Date: Wednesday, October 23, 2024
- Presentation Time: 13:30 to 15:00 CEST
- Room: Concourse Level I & Mezzanine Concourse
- Poster ID: P0174
To meet with NewBiologix at ESGCT, reach out to Déborah Ley at contact@newbiologix.com.
